← Ишга қайтиш
Ушбу иш иқтибос қилган ишлар
67 та иш
Иш: Molecular dynamics insights into the redox effects on PD-1/PD-L1 and PD-1/PD-L2 interactions
The evolution of cancer surgery and future perspectives
Lynda Wyld, Riccardo A. Audisio, Graeme J. Poston
Шарҳ мақола20143 иқтибосABIPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener +4
Шарҳ мақола20163 иқтибосABIImmune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani +6
Шарҳ мақола20223 иқтибосABIPD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li
Мақола20203 иқтибосABIPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo +1
Шарҳ мақола20173 иқтибосABINon-thermal plasma-induced immunogenic cell death in cancer
Marian Khalili, Lynsey Daniels, Abraham Lin +5
Мақола20192 иқтибосABIGeneration and propagation of radical reactions on proteins
Clare L. Hawkins, Michael J. Davies
Шарҳ мақола20012 иқтибосABIPD-1 and Its Ligands in Tolerance and Immunity
Mary Keir, Manish J. Butte, Gordon J. Freeman +1
Шарҳ мақола20082 иқтибосABILocal and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
Xiao Han, Hongjun Li, Daojia Zhou +2
Мақола20202 иқтибосABITransmembrane domain–driven PD-1 dimers mediate T cell inhibition
Elliot A. Philips, Jia Liu, Audun Kvalvaag +16
Мақола20242 иқтибосABIGlycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications
Jingyi Liu, Ximo Xu, Hao Zhong +5
Шарҳ мақола20242 иқтибосABIProteomic Investigation of Immune Checkpoints and Some of Their Inhibitors
Marco Agostini, Pietro Traldi, Mahmoud Hamdan
Шарҳ мақола20242 иқтибосABI